Epigenetic dynamics in cancer stem cell dormancy

1.

Afifi, A. M., Saad, A. M., Al-Husseini, M. J., Elmehrath, A. O., Northfelt, D. W., & Sonbol, M. B. (2019). Causes of death after breast cancer diagnosis: a US population-based analysis. Cancer. https://doi.org/10.1002/cncr.32648.

2.

Tamimi, A. F., & Juweid, M. (2017). Epidemiology and outcome of glioblastoma. In S. De Vleeschouwer (Ed.), Glioblastoma Brisbane (AU). Chapter 8, 143–154

3.

Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L., & Rich, J. N. (2015). Cancer stem cells in glioblastoma. Genes & Development, 29(12), 1203–1217. https://doi.org/10.1101/gad.261982.115.CrossRef

4.

Omuro, A., & DeAngelis, L. M. (2013). Glioblastoma and other malignant gliomas: a clinical review. JAMA, 310(17), 1842–1850. https://doi.org/10.1001/jama.2013.280319.CrossRefPubMed

5.

Kahlert, U. D., Mooney, S. M., Natsumeda, M., Steiger, H. J., & Maciaczyk, J. (2017). Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways. International Journal of Cancer, 140(1), 10–22. https://doi.org/10.1002/ijc.30259.CrossRefPubMed

6.

Han, H. R., Park, S. A., Ahn, S., Jeun, S. S., & Ryu, C. H. (2019). Evaluation of combination treatment effect with TRAIL-secreting mesenchymal stem cells and compound C against glioblastoma. Anticancer Research, 39(12), 6635–6643. https://doi.org/10.21873/anticanres.13878.CrossRefPubMed

7.

Pantel, K., Alix-Panabieres, C., & Riethdorf, S. (2009). Cancer micrometastases. Nature Reviews. Clinical Oncology, 6(6), 339–351. https://doi.org/10.1038/nrclinonc.2009.44.CrossRefPubMed

8.

Patel, S. A., Ramkissoon, S. H., Bryan, M., Pliner, L. F., Dontu, G., Patel, P. S., et al. (2012). Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Scientific Reports, 2, 906–906. https://doi.org/10.1038/srep00906.CrossRefPubMedPubMedCentral

9.

Chrun, E. S., Modolo, F., & Daniel, F. I. (2017). Histone modifications: a review about the presence of this epigenetic phenomenon in carcinogenesis. Pathology, Research and Practice, 213(11), 1329–1339. https://doi.org/10.1016/j.prp.2017.06.013.CrossRefPubMed

10.

Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics, 40(5), 499–507. https://doi.org/10.1038/ng.127.CrossRefPubMedPubMedCentral

11.

Suva, M. L., Riggi, N., & Bernstein, B. E. (2013). Epigenetic reprogramming in cancer. Science, 339(6127), 1567–1570. https://doi.org/10.1126/science.1230184.CrossRefPubMed

12.

Loh, K. M., & Lim, B. (2011). A precarious balance: pluripotency factors as lineage specifiers. Cell Stem Cell, 8(4), 363–369. https://doi.org/10.1016/j.stem.2011.03.013.CrossRefPubMed

13.

Thomson, M., Liu, S. J., Zou, L. N., Smith, Z., Meissner, A., & Ramanathan, S. (2011). Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell, 145(6), 875–889. https://doi.org/10.1016/j.cell.2011.05.017.CrossRefPubMedPubMedCentral

14.

Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676. https://doi.org/10.1016/j.cell.2006.07.024.CrossRef

15.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861–872. https://doi.org/10.1016/j.cell.2007.11.019.CrossRefPubMed

16.

Iwafuchi-Doi, M., & Zaret, K. S. (2014). Pioneer transcription factors in cell reprogramming. Genes & Development, 28(24), 2679–2692. https://doi.org/10.1101/gad.253443.114.CrossRef

17.

Zhang, W., Bado, I., Wang, H., Lo, H. C., & Zhang, X. H. (2019). Bone metastasis: find your niche and fit in. Trends Cancer, 5(2), 95–110. https://doi.org/10.1016/j.trecan.2018.12.004.CrossRefPubMedPubMedCentral

18.

Rowland, B. D., Bernards, R., & Peeper, D. S. (2005). The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nature Cell Biology, 7(11), 1074–1082. https://doi.org/10.1038/ncb1314.CrossRefPubMed

19.

Utikal, J., Polo, J. M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R. M., et al. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 460(7259), 1145–1148. https://doi.org/10.1038/nature08285.CrossRefPubMedPubMedCentral

20.

Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J., Creyghton, M. P., et al. (2009). Direct cell reprogramming is a stochastic process amenable to acceleration. Nature, 462(7273), 595–601. https://doi.org/10.1038/nature08592.CrossRefPubMedPubMedCentral

21.

Hochedlinger, K., & Jaenisch, R. (2015). Induced pluripotency and epigenetic reprogramming. Cold Spring Harbor Perspectives in Biology, 7(12). https://doi.org/10.1101/cshperspect.a019448.

22.

De Carvalho, D. D., You, J. S., & Jones, P. A. (2010). DNA methylation and cellular reprogramming. Trends in Cell Biology, 20(10), 609–617. https://doi.org/10.1016/j.tcb.2010.08.003.CrossRefPubMedPubMedCentral

23.

Gao, Y., Chen, J., Li, K., Wu, T., Huang, B., Liu, W., et al. (2013). Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA methylation and hydroxymethylation in reprogramming. Cell Stem Cell, 12(4), 453–469. https://doi.org/10.1016/j.stem.2013.02.005.CrossRefPubMed

24.

Sardina, J. L., Collombet, S., Tian, T. V., Gomez, A., Di Stefano, B., Berenguer, C., et al. (2018). Transcription factors drive Tet2-mediated enhancer demethylation to reprogram cell fate. Cell Stem Cell, 23(5), 727–741.e729. https://doi.org/10.1016/j.stem.2018.08.016.CrossRefPubMed

25.

Du, Q., Wang, Z., & Schramm, V. L. (2016). Human DNMT1 transition state structure. Proceedings of the National Academy of Sciences of the United States of America, 113(11), 2916–2921. https://doi.org/10.1073/pnas.1522491113.CrossRefPubMedPubMedCentral

26.

Okashita, N., Kumaki, Y., Ebi, K., Nishi, M., Okamoto, Y., Nakayama, M., et al. (2014). PRDM14 promotes active DNA demethylation through the ten-eleven translocation (TET)-mediated base excision repair pathway in embryonic stem cells. Development, 141(2), 269–280. https://doi.org/10.1242/dev.099622.CrossRefPubMed

27.

Bostick, M., Kim, J. K., Esteve, P. O., Clark, A., Pradhan, S., & Jacobsen, S. E. (2007). UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science, 317(5845), 1760–1764. https://doi.org/10.1126/science.1147939.CrossRefPubMed

28.

Stathopoulou, A., Chhetri, J. B., Ambrose, J. C., Esteve, P. O., Ji, L., Erdjument-Bromage, H., et al. (2017). A novel requirement for DROSHA in maintenance of mammalian CG methylation. Nucleic Acids Research, 45(16), 9398–9412. https://doi.org/10.1093/nar/gkx695.CrossRefPubMedPubMedCentral

29.

Grosser, C., Wagner, N., Grothaus, K., & Horsthemke, B. (2015). Altering TET dioxygenase levels within physiological range affects DNA methylation dynamics of HEK293 cells. Epigenetics, 10(9), 819–833. https://doi.org/10.1080/15592294.2015.1073879.CrossRefPubMedPubMedCentral

30.

Spruijt, C. G., Gnerlich, F., Smits, A. H., Pfaffeneder, T., Jansen, P. W., Bauer, C., et al. (2013). Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell, 152(5), 1146–1159. https://doi.org/10.1016/j.cell.2013.02.004.CrossRefPubMed

31.

Liu, L., Mao, S. Q., Ray, C., Zhang, Y., Bell, F. T., Ng, S. F., et al. (2015). Differential regulation of genomic imprinting by TET proteins in embryonic stem cells. Stem Cell Research, 15(2), 435–443. https://doi.org/10.1016/j.scr.2015.08.010.CrossRefPubMedPubMedCentral

32.

Skiles, W. M., Kester, A., Pryor, J. H., Westhusin, M. E., Golding, M. C., & Long, C. R. (2018). Oxygen-induced alterations in the expression of chromatin modifying enzymes and the transcriptional regulation of imprinted genes. Gene Expression Patterns, 28, 1–11. https://doi.org/10.1016/j.gep.2018.01.001.CrossRefPubMed

33.

Li, X. L., Xu, J. H., Nie, J. H., & Fan, S. J. (2012). Exogenous expression of UHRF1 promotes proliferation and metastasis of breast cancer cells. Oncology Reports, 28(1), 375–383. https://doi.org/10.3892/or.2012.1792.CrossRefPubMed

34.

Unoki, M., Brunet, J., & Mousli, M. (2009). Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochemical Pharmacology, 78(10), 1279–1288. https://doi.org/10.1016/j.bcp.2009.05.035.CrossRefPubMed

35.

Maenohara, S., Unoki, M., Toh, H., Ohishi, H., Sharif, J., Koseki, H., et al. (2017). Role of UHRF1 in de novo DNA methylation in oocytes and maintenance methylation in preimplantation embryos. PLoS Genetics, 13(10), e1007042. https://doi.org/10.1371/journal.pgen.1007042.CrossRefPubMedPubMedCentral

36.

Gordon, C. A., Hartono, S. R., & Chedin, F. (2013). Inactive DNMT3B splice variants modulate de novo DNA methylation. PLoS One, 8(7), e69486. https://doi.org/10.1371/journal.pone.0069486.CrossRefPubMedPubMedCentral

37.

Noh, K. M., Wang, H., Kim, H. R., Wenderski, W., Fang, F., Li, C. H., et al. (2015). Engineering of a histone-recognition domain in Dnmt3a alters the epigenetic landscape and phenotypic features of mouse ESCs. Molecular Cell, 59(1), 89–103. https://doi.org/10.1016/j.molcel.2015.05.017.CrossRefPubMedPubMedCentral

38.

Jeltsch, A., & Jurkowska, R. Z. (2016). Allosteric control of mammalian DNA methyltransferases - a new regulatory paradigm. Nucleic Acids Research, 44(18), 8556–8575. https://doi.org/10.1093/nar/gkw723.CrossRefPubMedPubMedCentral

39.

Duvall-Noelle, N., Karwandyar, A., Richmond, A., & Raman, D. (2016). LASP-1: a nuclear hub for the UHRF1-DNMT1-G9a-Snail1 complex. Oncogene, 35(9), 1122–1133. https://doi.org/10.1038/onc.2015.166.CrossRefPubMed

40.

Xue, B., Zhao, J., Feng, P., Xing, J., Wu, H., & Li, Y. (2019). Epigenetic mechanism and target therapy of UHRF1 protein complex in malignancies. Oncotargets and Therapy, 12, 549–559. https://doi.org/10.2147/ott.S192234.CrossRefPubMedPubMedCentral

41.

Snowden, A. W., Gregory, P. D., Case, C. C., & Pabo, C. O. (2002). Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Current Biology, 12(24), 2159–2166. https://doi.org/10.1016/s0960-9822(02)01391-x.CrossRefPubMed

42.

Ko, M., An, J., Pastor, W. A., Koralov, S. B., Rajewsky, K., & Rao, A. (2015). TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunological Reviews, 263(1), 6–21. https://doi.org/10.1111/imr.12239.CrossRefPubMedPubMedCentral

43.

Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science, 324(5929), 930–935. https://doi.org/10.1126/science.1170116.CrossRefPubMedPubMedCentral

44.

Hu, X., Zhang, L., Mao, S. Q., Li, Z., Chen, J., Zhang, R. R., et al. (2014). Tet and TDG mediate DNA demethylation essential for mesenchymal-to-epithelial transition in somatic cell reprogramming. Cell Stem Cell, 14(4), 512–522. https://doi.org/10.1016/j.stem.2014.01.001.CrossRefPubMed

45.

Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., et al. (2016). Editing DNA methylation in the mammalian genome. Cell, 167(1), 233–247.e217. https://doi.org/10.1016/j.cell.2016.08.056.CrossRefPubMedPubMedCentral

46.

Wu, M. J., Kim, M. R., Chen, Y. S., Yang, J. Y., & Chang, C. J. (2017). Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKCzeta pathway. Oncogene, 36(22), 3193–3206. https://doi.org/10.1038/onc.2016.467.CrossRefPubMedPubMedCentral

47.

Xu, Y., Liu, S. Y., Li, J., Zhang, L., Chen, D., Zhang, J. P., et al. (2018). Real-time sensing of TET2-mediated DNA demethylation in vitro by metal-organic framework-based oxygen sensor for mechanism analysis and stem-cell behavior prediction. Analytical Chemistry, 90(15), 9330–9337. https://doi.org/10.1021/acs.analchem.8b01941.CrossRefPubMed

48.

Rasmussen, K. D., & Helin, K. (2016). Role of TET enzymes in DNA methylation, development, and cancer. Genes & Development, 30(7), 733–750. https://doi.org/10.1101/gad.276568.115.CrossRef

49.

Wang, L., Zhou, Y., Xu, L., Xiao, R., Lu, X., Chen, L., et al. (2015). Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature, 523(7562), 621–625. https://doi.org/10.1038/nature14482.CrossRefPubMedPubMedCentral

50.

Kellinger, M. W., Song, C. X., Chong, J., Lu, X. Y., He, C., & Wang, D. (2012). 5-formylcytosine and 5-carboxylcytosine reduce the rate and substrate specificity of RNA polymerase II transcription. Nature Structural & Molecular Biology, 19(8), 831–833. https://doi.org/10.1038/nsmb.2346.CrossRef

51.

Globisch, D., Munzel, M., Muller, M., Michalakis, S., Wagner, M., Koch, S., et al. (2010). Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One, 5(12), e15367. https://doi.org/10.1371/journal.pone.0015367.CrossRefPubMedPubMedCentral

52.

Zhang, L. Y., Han, C. S., Li, P. L., & Zhang, X. C. (2016). 5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. Japanese Journal of Clinical Oncology, 46(5), 427–434. https://doi.org/10.1093/jjco/hyw002.CrossRefPubMed

53.

Zhang, P., Huang, B., Xu, X., & Sessa, W. C. (2013). Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochemical and Biophysical Research Communications, 437(3), 368–373. https://doi.org/10.1016/j.bbrc.2013.06.082.CrossRefPubMedPubMedCentral

54.

Putiri, E. L., Tiedemann, R. L., Thompson, J. J., Liu, C., Ho, T., Choi, J. H., et al. (2014). Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. Genome Biology, 15(6), R81. https://doi.org/10.1186/gb-2014-15-6-r81.CrossRefPubMedPubMedCentral

55.

Iyer, L. M., Abhiman, S., & Aravind, L. (2011). Natural history of eukaryotic DNA methylation systems. Progress in Molecular Biology and Translational Science, 101, 25–104. https://doi.org/10.1016/b978-0-12-387685-0.00002-0.CrossRefPubMed

56.

Iyer, L. M., Tahiliani, M., Rao, A., & Aravind, L. (2009). Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle, 8(11), 1698–1710. https://doi.org/10.4161/cc.8.11.8580.CrossRefPubMedPubMedCentral

57.

Ko, M., An, J., Bandukwala, H. S., Chavez, L., Aijo, T., Pastor, W. A., et al. (2013). Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature, 497(7447), 122–126. https://doi.org/10.1038/nature12052.CrossRefPubMedPubMedCentral

58.

Nguyen, A. V., Albers, C. G., & Holcombe, R. F. (2010). Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. International Journal of Molecular Medicine, 26(1), 121–125. https://doi.org/10.3892/ijmm_00000443.CrossRefPubMed

59.

Zhang, P., Rausch, C., Hastert, F. D., Boneva, B., Filatova, A., Patil, S. J., et al. (2017). Methyl-CpG binding domain protein 1 regulates localization and activity of Tet1 in a CXXC3 domain-dependent manner. Nucleic Acids Research, 45(12), 7118–7136. https://doi.org/10.1093/nar/gkx281.CrossRefPubMedPubMedCentral

60.

Ludwig, A. K., Zhang, P., Hastert, F. D., Meyer, S., Rausch, C., Herce, H. D., et al. (2017). Binding of MBD proteins to DNA blocks Tet1 function thereby modulating transcriptional noise. Nucleic Acids Research, 45(5), 2438–2457. https://doi.org/10.1093/nar/gkw1197.CrossRefPubMed

61.

Rausch, C., Hastert, F. D., & Cardoso, M. C. (2019). DNA modification readers and writers and their interplay. Journal of Molecular Biology. https://doi.org/10.1016/j.jmb.2019.12.018.

62.

Li, L., Chen, B. F., & Chan, W. Y. (2015). An epigenetic regulator: methyl-CpG-binding domain protein 1 (MBD1). International Journal of Molecular Sciences, 16(3), 5125–5140. https://doi.org/10.3390/ijms16035125.CrossRefPubMedPubMedCentral

63.

Wood, K. H., & Zhou, Z. (2016). Emerging molecular and biological functions of MBD2, a reader of DNA methylation. Frontiers in Genetics, 7, 93. https://doi.org/10.3389/fgene.2016.00093.CrossRefPubMedPubMedCentral

64.

Takai, H., Masuda, K., Sato, T., Sakaguchi, Y., Suzuki, T., Suzuki, T., et al. (2014). 5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Reports, 9(1), 48–60. https://doi.org/10.1016/j.celrep.2014.08.071.CrossRefPubMed

65.

Forloni, M., Gupta, R., Nagarajan, A., Sun, L. S., Dong, Y., Pirazzoli, V., et al. (2016). Oncogenic EGFR represses the TET1 DNA demethylase to induce silencing of tumor suppressors in cancer cells. Cell Reports, 16(2), 457–471. https://doi.org/10.1016/j.celrep.2016.05.087.CrossRefPubMedPubMedCentral

66.

Good, C. R., Madzo, J., Patel, B., Maegawa, S., Engel, N., Jelinek, J., et al. (2017). A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer. Nucleic Acids Research, 45(14), 8269–8281. https://doi.org/10.1093/nar/gkx435.CrossRefPubMedPubMedCentral

67.

Inoue-Choi, M., Nelson, H. H., Robien, K., Arning, E., Bottiglieri, T., Koh, W. P., et al. (2013). Plasma S-adenosylmethionine, DNMT polymorphisms, and peripheral blood LINE-1 methylation among healthy Chinese adults in Singapore. BMC Cancer, 13, 389. https://doi.org/10.1186/1471-2407-13-389.CrossRefPubMedPubMedCentral

68.

Kohli, R. M., & Zhang, Y. (2013). TET enzymes, TDG and the dynamics of DNA demethylation. Nature, 502(7472), 472–479. https://doi.org/10.1038/nature12750.CrossRefPubMedPubMedCentral

69.

Cavuoto, P., & Fenech, M. F. (2012). A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treatment Reviews, 38(6), 726–736. https://doi.org/10.1016/j.ctrv.2012.01.004.CrossRefPubMed

70.

Soda, K. (2018). Polyamine metabolism and gene methylation in conjunction with one-carbon metabolism. International Journal of Molecular Sciences, 19(10). https://doi.org/10.3390/ijms19103106.

71.

Mahmoud, A. M., & Ali, M. M. (2019). Methyl donor micronutrients that modify DNA methylation and cancer outcome. Nutrients, 11(3). https://doi.org/10.3390/nu11030608.

72.

Gut, P., & Verdin, E. (2013). The nexus of chromatin regulation and intermediary metabolism. Nature, 502(7472), 489–498. https://doi.org/10.1038/nature12752.CrossRefPubMed

73.

Kaelin Jr., W. G., & McKnight, S. L. (2013). Influence of metabolism on epigenetics and disease. Cell, 153(1), 56–69. https://doi.org/10.1016/j.cell.2013.03.004.CrossRefPubMedPubMedCentral

74.

Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., et al. (2012). Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes & Development, 26(12), 1326–1338. https://doi.org/10.1101/gad.191056.112.CrossRef

75.

Xu, Y., Wu, F., Tan, L., Kong, L., Xiong, L., Deng, J., et al. (2011). Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Molecular Cell, 42(4), 451–464. https://doi.org/10.1016/j.molcel.2011.04.005.CrossRefPubMedPubMedCentral

76.

Flavahan, W. A., Drier, Y., Liau, B. B., Gillespie, S. M., Venteicher, A. S., Stemmer-Rachamimov, A. O., et al. (2016). Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature, 529(7584), 110–114. https://doi.org/10.1038/nature16490.CrossRefPubMed

77.

Cimmino, L., Neel, B. G., & Aifantis, I. (2018). Vitamin C in stem cell reprogramming and cancer. Trends in Cell Biology, 28(9), 698–708. https://doi.org/10.1016/j.tcb.2018.04.001.CrossRefPubMedPubMedCentral

78.

Aoki, K., & Natsume, A. (2019). Overview of DNA methylation in adult diffuse gliomas. Brain Tumor Pathology, 36(2), 84–91. https://doi.org/10.1007/s10014-019-00339-w.CrossRefPubMed

79.

Bouras, E., Karakioulaki, M., Bougioukas, K. I., Aivaliotis, M., Tzimagiorgis, G., & Chourdakis, M. (2019). Gene promoter methylation and cancer: an umbrella review. Gene, 710, 333–340. https://doi.org/10.1016/j.gene.2019.06.023.CrossRefPubMed

80.

Roll, J. D., Rivenbark, A. G., Sandhu, R., Parker, J. S., Jones, W. D., Carey, L. A., et al. (2013). Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Experimental and Molecular Pathology, 95(3), 276–287. https://doi.org/10.1016/j.yexmp.2013.09.001.CrossRefPubMed

81.

Phuong, N. T., Kim, S. K., Lim, S. C., Kim, H. S., Kim, T. H., Lee, K. Y., et al. (2011). Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Research and Treatment, 130(1), 73–83. https://doi.org/10.1007/s10549-010-1304-2.CrossRefPubMed

82.

Yang, L., Yu, S. J., Hong, Q., Yang, Y., & Shao, Z. M. (2015). Reduced expression of TET1, TET2, TET3 and TDG mRNAs are associated with poor prognosis of patients with early breast cancer. PLoS One, 10(7), e0133896. https://doi.org/10.1371/journal.pone.0133896.CrossRefPubMedPubMedCentral

83.

Thienpont, B., Galle, E., & Lambrechts, D. (2016). TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management. Epigenomics, 8(11), 1445–1448. https://doi.org/10.2217/epi-2016-0126.CrossRefPubMed

84.

Kao, S. H., Wu, K. J., & Lee, W. H. (2016). Hypoxia, epithelial-mesenchymal transition, and TET-mediated epigenetic changes. Journal of Clinical Medicine, 5(2). https://doi.org/10.3390/jcm5020024.

85.

Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2014). Rare insights into cancer biology. Oncogene, 33(20), 2547–2556. https://doi.org/10.1038/onc.2013.222.CrossRefPubMed

86.

Laukka, T., Mariani, C. J., Ihantola, T., Cao, J. Z., Hokkanen, J., Kaelin Jr., W. G., et al. (2016). Fumarate and succinate regulate expression of hypoxia-inducible genes via TET enzymes. The Journal of Biological Chemistry, 291(8), 4256–4265. https://doi.org/10.1074/jbc.M115.688762.CrossRefPubMed

87.

Liu, Y., Jiang, W., Liu, J., Zhao, S., Xiong, J., Mao, Y., et al. (2012). IDH1 mutations inhibit multiple alpha-ketoglutarate-dependent dioxygenase activities in astroglioma. Journal of Neuro-Oncology, 109(2), 253–260. https://doi.org/10.1007/s11060-012-0914-4.CrossRefPubMed

88.

Agnihotri, S., Aldape, K. D., & Zadeh, G. (2014). Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. Neurosurgical Focus, 37(6), E13. https://doi.org/10.3171/2014.9.Focus14505.CrossRefPubMed

89.

Budczies, J., & Denkert, C. (2016). Tissue-based metabolomics to analyze the breast cancer metabolome. Recent Results in Cancer Research, 207, 157–175. https://doi.org/10.1007/978-3-319-42118-6_7.CrossRefPubMed

90.

Hervouet, E., Peixoto, P., Delage-Mourroux, R., Boyer-Guittaut, M., & Cartron, P. F. (2018). Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clinical Epigenetics, 10, 17. https://doi.org/10.1186/s13148-018-0450-y.CrossRefPubMedPubMedCentral

91.

Inoue, S., Li, W. Y., Tseng, A., Beerman, I., Elia, A. J., Bendall, S. C., et al. (2016). Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell, 30(2), 337–348. https://doi.org/10.1016/j.ccell.2016.05.018.CrossRefPubMedPubMedCentral

92.

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360(8), 765–773. https://doi.org/10.1056/NEJMoa0808710.CrossRefPubMedPubMedCentral

93.

Muller, T., Gessi, M., Waha, A., Isselstein, L. J., Luxen, D., Freihoff, D., et al. (2012). Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. The American Journal of Pathology, 181(2), 675–683. https://doi.org/10.1016/j.ajpath.2012.04.017.CrossRefPubMed

94.

Turcan, S., Fabius, A. W., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., et al. (2013). Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget, 4(10), 1729–1736. https://doi.org/10.18632/oncotarget.1412.CrossRefPubMedPubMedCentral

95.

Zhou, Z., Li, H. Q., & Liu, F. (2018). DNA methyltransferase inhibitors and their therapeutic potential. Current Topics in Medicinal Chemistry, 18(28), 2448–2457. https://doi.org/10.2174/1568026619666181120150122.CrossRefPubMed

96.

Chen, A., Sceneay, J., Godde, N., Kinwel, T., Ham, S., Thompson, E. W., et al. (2018). Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene, 37(31), 4214–4225. https://doi.org/10.1038/s41388-018-0259-3.CrossRefPubMed

97.

Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348). https://doi.org/10.1126/science.aal2380.

98.

Prasad, P., Mittal, S. A., Chongtham, J., Mohanty, S., & Srivastava, T. (2017). Hypoxia-mediated epigenetic regulation of stemness in brain tumor cells. Stem Cells, 35(6), 1468–1478. https://doi.org/10.1002/stem.2621.CrossRefPubMed

99.

Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367(6464), 645–648. https://doi.org/10.1038/367645a0.CrossRefPubMed

100.

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414(6859), 105–111. https://doi.org/10.1038/35102167.CrossRefPubMed

101.

Giordano, A., Gao, H., Cohen, E. N., Anfossi, S., Khoury, J., Hess, K., et al. (2013). Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 24(10), 2515–2521. https://doi.org/10.1093/annonc/mdt223.CrossRef

102.

Bu, Y., & Cao, D. (2012). The origin of cancer stem cells. Frontiers in Bioscience (Scholar Edition), 4, 819–830. https://doi.org/10.2741/s302.CrossRef

103.

Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017). Drug resistance driven by cancer stem cells and their niche. International Journal of Molecular Sciences, 18(12). https://doi.org/10.3390/ijms18122574.

104.

Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007). The biology of cancer stem cells. Annual Review of Cell and Developmental Biology, 23(1), 675–699. https://doi.org/10.1146/annurev.cellbio.22.010305.104154.CrossRefPubMed

105.

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M.F. F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100(7), 3983–3988

106.

Hwang-Verslues, W. W., Kuo, W.-H., Chang, P.-H., Pan, C.-C., Wang, H.-H., Tsai, S.-T., et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem. Cell Markers. PLoS ONE, 4(12), 8377–8377. https://doi.org/10.1371/journal.pone.0008377.

107.

Figueiredo, E., Zaghloul, K., Zhang, Y., Tan, S. T., Bradshaw, A., Wickremsekera, A., et al. (2016). Cancer stem cell hierarchy in glioblastoma multiforme. 3, 2, doi:https://doi.org/10.3389/fsurg.2016.00021.

108.

Bliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., et al. (2016). Mesenchymal stem cell–derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Research, 76(19), 5832–5844. https://doi.org/10.1158/0008-5472.CAN-16-1092.CrossRefPubMed

109.

Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4), 704–715. https://doi.org/10.1016/j.cell.2008.03.027.CrossRefPubMedPubMedCentral

110.

Sell, S. (2004). Stem cell origin of cancer and differentiation therapy. Critical Reviews in Oncology/Hematology, 51(1), 1–28. https://doi.org/10.1016/J.CRITREVONC.2004.04.007.CrossRefPubMed

111.

Wicha, M. S., Liu, S., & Dontu, G. (2006). Cancer stem cells: an old idea-A paradigm shift. Cancer Research, 66(4), 1883–1890. https://doi.org/10.1158/0008-5472.CAN-05-3153.CrossRefPubMed

112.

Marsden, C. G., Wright, M. J., Carrier, L., Moroz, K., & Rowan, B. G. (2012). Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone. PLoS One, 7(11), e47587–e47587. https://doi.org/10.1371/journal.pone.0047587.CrossRefPubMedPubMedCentral

113.

Shiozawa, Y., & Taichman, R. S. (2012). Cancer stem cells and the bone marrow microenvironment. Bonekey Reports, 2012(1). https://doi.org/10.1038/bonekey.2012.48.

114.

Birbrair, A., & Frenette, P. S. (2016). Niche heterogeneity in the bone marrow. Annals of the New York Academy of Sciences, 1370(1), 82–96. https://doi.org/10.1111/nyas.13016.CrossRefPubMedPubMedCentral

115.

Morrison, S. J., & Scadden, D. T. (2014). The bone marrow niche for haematopoietic stem cells. Nature, 505(7483), 327–334. https://doi.org/10.1038/nature12984.CrossRefPubMedPubMedCentral

116.

Yu, V. W., & Scadden, D. T. (2016). Hematopoietic stem cell and its bone marrow niche. Current Topics in Developmental Biology, 118, 21–44. https://doi.org/10.1016/bs.ctdb.2016.01.009.CrossRefPubMedPubMedCentral

117.

Guerra, D. A. P., Paiva, A. E., Sena, I. F. G., Azevedo, P. O., Batista Jr., M. L., Mintz, A., et al. (2018). Adipocytes role in the bone marrow niche. Cytometry. Part A, 93(2), 167–171. https://doi.org/10.1002/cyto.a.23301.CrossRef

118.

Rameshwar, P. (2010). Breast cancer cell dormancy in bone marrow: potential therapeutic targets within the marrow microenvironment. Expert Review of Anticancer Therapy, 10(2), 129–132. https://doi.org/10.1586/era.10.3.CrossRefPubMed

119.

Eltoukhy, H. S., Sinha, G., Moore, C. A., Gergues, M., & Rameshwar, P. (2018). Secretome within the bone marrow microenvironment: a basis for mesenchymal stem cell treatment and role in cancer dormancy. Biochimie, 155, 92–103. https://doi.org/10.1016/j.biochi.2018.05.018.CrossRefPubMed

120.

Ridge, S. M., Sullivan, F. J., & Glynn, S. A. (2017). Mesenchymal stem cells: key players in cancer progression. Molecular Cancer, 16(1), 31. https://doi.org/10.1186/s12943-017-0597-8.CrossRefPubMedPubMedCentral

121.

Ruivo, C. F., Adem, B., Silva, M., & Melo, S. A. (2017). The biology of cancer exosomes: insights and new perspectives. Cancer Research, 77(23), 6480–6488. https://doi.org/10.1158/0008-5472.CAN-17-0994.CrossRefPubMed

122.

Walker, N. D., Elias, M., Guiro, K., Bhatia, R., Greco, S. J., Bryan, M., et al. (2019). Exosomes from differentially activated macrophages influence dormancy or resurgence of breast cancer cells within bone marrow stroma. Cell Death & Disease, 10(2), 59. https://doi.org/10.1038/s41419-019-1304-z.CrossRef

123.

Wu, J. I., & Wang, L. H. (2019). Emerging roles of gap junction proteins connexins in cancer metastasis, chemoresistance and clinical application. Journal of Biomedical Science, 26(1), 8. https://doi.org/10.1186/s12929-019-0497-x.CrossRefPubMedPubMedCentral

124.

Zefferino, R., Piccoli, C., Gioia, S. D., Capitanio, N., & Conese, M. (2019). Gap junction intercellular communication in the carcinogenesis hallmarks: is this a phenomenon or epiphenomenon? Cells, 8(8). https://doi.org/10.3390/cells8080896.

125.

Sinyuk, M., Mulkearns-Hubert, E. E., Reizes, O., & Lathia, J. (2018). Cancer connectors: connexins, gap junctions, and communication. Frontiers in Oncology, 8, 646. https://doi.org/10.3389/fonc.2018.00646.CrossRefPubMedPubMedCentral

126.

Busby, M., Hallett, M. T., & Plante, I. (2018). The complex subtype-dependent role of connexin 43 (GJA1) in breast cancer. International Journal of Molecular Sciences, 19(3). https://doi.org/10.3390/ijms19030693.

127.

Oliveira, R., Christov, C., Guillamo, J. S., de Bouard, S., Palfi, S., Venance, L., et al. (2005). Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biology, 6(1), 7. https://doi.org/10.1186/1471-2121-6-7.CrossRefPubMedPubMedCentral

128.

Munoz, J. L., Bliss, S. A., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2013). Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Molecular Therapy--Nucleic Acids, 2, e126. https://doi.org/10.1038/mtna.2013.60.CrossRefPubMedPubMedCentral

129.

Park, J. M., Munoz, J. L., Won, B. W., Bliss, S. A., Greco, S. J., Patel, S. A., et al. (2013). Exogenous CXCL12 activates protein kinase C to phosphorylate connexin 43 for gap junctional intercellular communication among confluent breast cancer cells. Cancer Letters, 331(1), 84–91. https://doi.org/10.1016/j.canlet.2012.12.007.CrossRefPubMed

130.

Poddar, S., Kesharwani, D., & Datta, M. (2017). Interplay between the miRNome and the epigenetic machinery: implications in health and disease. Journal of Cellular Physiology, 232(11), 2938–2945. https://doi.org/10.1002/jcp.25819.CrossRefPubMed

131.

Piletic, K., & Kunej, T. (2016). MicroRNA epigenetic signatures in human disease. Archives of Toxicology, 90(10), 2405–2419. https://doi.org/10.1007/s00204-016-1815-7.CrossRefPubMed

132.

Tu, J., Ng, S. H., Luk, A. C., Liao, J., Jiang, X., Feng, B., et al. (2015). MicroRNA-29b/Tet1 regulatory axis epigenetically modulates mesendoderm differentiation in mouse embryonic stem cells. Nucleic Acids Research, 43(16), 7805–7822. https://doi.org/10.1093/nar/gkv653.CrossRefPubMedPubMedCentral

133.

Iwama, H., Kato, K., Imachi, H., Murao, K., & Masaki, T. (2018). Human microRNAs preferentially target genes with intermediate levels of expression and its formation by mammalian evolution. PLoS One, 13(5), e0198142. https://doi.org/10.1371/journal.pone.0198142.CrossRefPubMedPubMedCentral

134.

Liu, X., Chen, X., Yu, X., Tao, Y., Bode, A. M., Dong, Z., et al. (2013). Regulation of microRNAs by epigenetics and their interplay involved in cancer. Journal of Experimental & Clinical Cancer Research, 32, 96. https://doi.org/10.1186/1756-9966-32-96.CrossRef

135.

Daniunaite, K., Dubikaityte, M., Gibas, P., Bakavicius, A., Rimantas Lazutka, J., Ulys, A., et al. (2017). Clinical significance of miRNA host gene promoter methylation in prostate cancer. Human Molecular Genetics, 26(13), 2451–2461. https://doi.org/10.1093/hmg/ddx138.CrossRefPubMed

136.

Pathania, R. a. R. S. a. E. S. a. P. R. a. Y. P. a. C. S. a. V.-K. R. a. A. P. a. G.-P. J. P. a. S. (2015). DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nature Communications, 6(1), 6910. https://doi.org/10.1038/ncomms7910.CrossRefPubMedPubMedCentral

137.

Oltra, S. S., Peña-Chilet, M., Flower, K., Martinez, M. T., Alonso, E., Burgues, O., et al. (2019). Acceleration in the DNA methylation age in breast cancer tumours from very young women. Scic Rep, 9(1). https://doi.org/10.1038/s41598-019-51457-6.

138.

El Helou, R., Wicinski, J., Guille, A., Adélaïde, J., Finetti, P., Bertucci, F., et al. (2014). Brief reports: a distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. Stem Cells, 32(11), 3031–3036. https://doi.org/10.1002/stem.1792.CrossRefPubMed

139.

Taube, J. H., Malouf, G. G., Lu, E., Sphyris, N., Vijay, V., Ramachandran, P. P., et al. (2013). Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports, 3, 2687. https://doi.org/10.1038/srep02687.CrossRefPubMedPubMedCentral

140.

Neves, R., Scheel, C., Weinhold, S., Honisch, E., Iwaniuk, K. M., Trompeter, H. I., et al. (2010). Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Research Notes, 3, 219. https://doi.org/10.1186/1756-0500-3-219.CrossRefPubMedPubMedCentral

141.

Nass, S. J., Herman, J. G., Gabrielson, E., Iversen, P. W., Parl, F. F., Davidson, N. E., et al. (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Research, 60(16), 4346–4348.PubMed

142.

Joo, J. E., Dowty, J. G., Milne, R. L., Wong, E. M., Dugue, P. A., English, D., et al. (2018). Heritable DNA methylation marks associated with susceptibility to breast cancer. Nature Communications, 9(1), 867. https://doi.org/10.1038/s41467-018-03058-6.CrossRefPubMedPubMedCentral

143.

Fleischer, T., Tekpli, X., Mathelier, A., Wang, S., Nebdal, D., Dhakal, H. P., et al. (2017). DNA methylation at enhancers identifies distinct breast cancer lineages. Nature Communications, 8, 1379. https://doi.org/10.1038/s41467-017-00510-x.CrossRefPubMedPubMedCentral

144.

Hernandez-Vargas, H., Ouzounova, M., Le Calvez-Kelm, F., Lambert, M. P., McKay-Chopin, S., Tavtigian, S. V., et al. (2011). Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics, 6(4), 428–439. https://doi.org/10.4161/epi.6.4.14515.CrossRefPubMed

145.

Chimonidou, M., Strati, A., Tzitzira, A., Sotiropoulou, G., Malamos, N., Georgoulias, V., et al. (2011). DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clinical Chemistry, 57(8), 1169–1177. https://doi.org/10.1373/clinchem.2011.165902.CrossRefPubMed

146.

Darvin, P., Sasidharan Nair, V., & Elkord, E. (2019). PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. Journal of Oncology, 2019, 3958908. https://doi.org/10.1155/2019/3958908.CrossRefPubMedPubMedCentral

147.

Rankin, E. B., & Giaccia, A. J. (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death and Differentiation, 15(4), 678–685. https://doi.org/10.1038/cdd.2008.21.CrossRefPubMedPubMedCentral

148.

Guo, C., Chen, L. H., Huang, Y., Chang, C. C., Wang, P., Pirozzi, C. J., et al. (2013). KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget, 4(11), 2144–2153. https://doi.org/10.18632/oncotarget.1555.CrossRefPubMedPubMedCentral

149.

Wang, L., Ozark, P. A., Smith, E. R., Zhao, Z., Marshall, S. A., Rendleman, E. J., et al. (2018). TET2 coactivates gene expression through demethylation of enhancers. Science Advances, 4(11), eaau6986. https://doi.org/10.1126/sciadv.aau6986.CrossRefPubMedPubMedCentral

150.

Chen, J. Y., Luo, C. W., Lai, Y. S., Wu, C. C., & Hung, W. C. (2017). Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis, 6(8), e369. https://doi.org/10.1038/oncsis.2017.71.CrossRefPubMedPubMedCentral

151.

Yu, Y., Qi, J., Xiong, J., Jiang, L., Cui, D., He, J., et al. (2019). Epigenetic co-deregulation of EZH2/TET1 is a senescence-countering, actionable vulnerability in triple-negative breast cancer. Theranostics, 9(3), 761–777. https://doi.org/10.7150/thno.29520.CrossRefPubMedPubMedCentral

152.

Wu, M. Z., Chen, S. F., Nieh, S., Benner, C., Ger, L. P., Jan, C. I., et al. (2015). Hypoxia drives breast tumor malignancy through a TET-TNFalpha-p38-MAPK signaling axis. Cancer Research, 75(18), 3912–3924. https://doi.org/10.1158/0008-5472.CAN-14-3208.CrossRefPubMed

153.

Thienpont, B., Steinbacher, J., Zhao, H., D’Anna, F., Kuchnio, A., Ploumakis, A., et al. (2016). Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature, 537(7618), 63–68. https://doi.org/10.1038/nature19081.CrossRefPubMedPubMedCentral

154.

Ryan Good, C., Panjarian, S., Kelly, A. D., Madzo, J., Patel, B., Jelinek, J., et al. (2018). Genome and epigenome TET1-mediated hypomethylation activates oncogenic signaling in triple-negative. Breast Cancer. https://doi.org/10.1158/0008-5472.CAN-17-2082.

155.

Hsu, C. H., Peng, K. L., Kang, M. L., Chen, Y. R., Yang, Y. C., Tsai, C. H., et al. (2012). TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Reports, 2(3), 568–579. https://doi.org/10.1016/j.celrep.2012.08.030.CrossRefPubMed

156.

Collignon, E., Canale, A., Al Wardi, C., Bizet, M., Calonne, E., Dedeurwaerder, S., et al. (2018). Immunity drives TET1 regulation in cancer through NF-kappaB. Science Advances, 4(6), eaap7309. https://doi.org/10.1126/sciadv.aap7309.CrossRefPubMedPubMedCentral

157.

Sant, D. W., Mustafi, S., Gustafson, C. B., Chen, J., Slingerland, J. M., & Wang, G. (2018). Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. Scientific Reports, 8(1), 5306. https://doi.org/10.1038/s41598-018-23714-7.CrossRefPubMedPubMedCentral

158.

Klughammer, J., Kiesel, B., Roetzer, T., Fortelny, N., Nemc, A., Nenning, K. H., et al. (2018). The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine, 24(10), 1611–1624. https://doi.org/10.1038/s41591-018-0156-x.CrossRefPubMedPubMedCentral

159.

Lee, E. J., Rath, P., Liu, J., Ryu, D., Pei, L., Noonepalle, S. K., et al. (2015). Identification of global DNA methylation signatures in glioblastoma-derived cancer stem cells. Journal of Genetics and Genomics, 42(7), 355–371. https://doi.org/10.1016/j.jgg.2015.06.003.CrossRefPubMedPubMedCentral

160.

Bulstrode, H., Johnstone, E., Marques-Torrejon, M. A., Ferguson, K. M., Bressan, R. B., Blin, C., et al. (2017). Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators. Genes & Development, 31(8), 757–773. https://doi.org/10.1101/gad.293027.116.CrossRef

161.

Gopisetty, G., Xu, J., Sampath, D., Colman, H., & Puduvalli, V. K. (2013). Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene, 32(26), 3119–3129. https://doi.org/10.1038/onc.2012.331.CrossRefPubMed

162.

Iwadate, Y., Suganami, A., Tamura, Y., Matsutani, T., Hirono, S., Shinozaki, N., et al. (2017). The pluripotent stem-cell marker alkaline phosphatase is highly expressed in refractory glioblastoma with DNA hypomethylation. Neurosurgery, 80(2), 248–256. https://doi.org/10.1093/neuros/nyw026.CrossRefPubMed

163.

Zhou, D., Wan, Y., Xie, D., Wang, Y., Wei, J., Yan, Q., et al. (2015). DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells. Experimental & Molecular Medicine, 47, e182. https://doi.org/10.1038/emm.2015.57.CrossRef

164.

Ning, X., Shi, Z., Liu, X., Zhang, A., Han, L., Jiang, K., et al. (2015). DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Letters, 359(2), 198–205. https://doi.org/10.1016/j.canlet.2015.01.005.CrossRefPubMed

165.

Hervouet, E., Vallette, F. M., & Cartron, P. F. (2010). Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death & Disease, 1, e8. https://doi.org/10.1038/cddis.2009.7.CrossRef

166.

Gu, X., Gong, H., Shen, L., & Gu, Q. (2018). MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. American Journal of Translational Research, 10(9), 2834–2847.PubMedPubMedCentral

167.

Sun, J., Tian, X., Zhang, J., Huang, Y., Lin, X., Chen, L., et al. (2017). Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion. Journal of Experimental & Clinical Cancer Research, 36(1), 100. https://doi.org/10.1186/s13046-017-0567-4.CrossRef

168.

Izumikawa, K., Ishikawa, H., Simpson, R. J., & Takahashi, N. (2018). Modulating the expression of Chtop, a versatile regulator of gene-specific transcription and mRNA export. RNA Biology, 15(7), 849–855. https://doi.org/10.1080/15476286.2018.1465795.CrossRefPubMedPubMedCentral

169.

Johnson, K. C., Houseman, E. A., King, J. E., von Herrmann, K. M., Fadul, C. E., & Christensen, B. C. (2016). 5-Hydroxymethylcytosine localizes to enhancer elements and is associated with survival in glioblastoma patients. Nature Communications, 7, 13177. https://doi.org/10.1038/ncomms13177.CrossRefPubMedPubMedCentral

170.

Carella, A., Tejedor, J. R., García, M. G., Urdinguio, R. G., Bayón, G. F., Sierra, M., et al. (2020). Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis. International Journal of Cancer, 146(2), 373–387. https://doi.org/10.1002/ijc.32520.CrossRefPubMed

171.

Qu, Q., Sun, G., Li, W., Yang, S., Ye, P., Zhao, C., et al. (2010). Orphan nuclear receptor TLX activates Wnt/Β-catenin signalling to stimulate neural stem cell proliferation and self-renewal. Nature Cell Biology, 12(1), 31–40. https://doi.org/10.1038/ncb2001.CrossRefPubMed

172.

Cui, Q., Yang, S., Ye, P., Tian, E., Sun, G., Zhou, J., et al. (2016). Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nature Communications, 7, 10637. https://doi.org/10.1038/ncomms10637.CrossRefPubMedPubMedCentral

173.

Zhou, D., Alver, B. M., Li, S., Hlady, R. A., Thompson, J. J., Schroeder, M. A., et al. (2018). Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biology, 19(1), 43–43. https://doi.org/10.1186/s13059-018-1420-6.CrossRefPubMedPubMedCentral

174.

Puig, I., Tenbaum, S. P., Chicote, I., Arques, O., Martinez-Quintanilla, J., Cuesta-Borras, E., et al. (2018). TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. The Journal of Clinical Investigation, 128(9), 3887–3905. https://doi.org/10.1172/jci96393.CrossRefPubMedPubMedCentral

175.

Garcia, M. G., Carella, A., Urdinguio, R. G., Bayon, G. F., Lopez, V., Tejedor, J. R., et al. (2018). Epigenetic dysregulation of TET2 in human glioblastoma. Oncotarget, 9(40), 25922–25934. https://doi.org/10.18632/oncotarget.25406.CrossRefPubMedPubMedCentral

176.

Huang, Y., Chavez, L., Chang, X., Wang, X., Pastor, W. A., Kang, J., et al. (2014). Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 111(4), 1361–1366. https://doi.org/10.1073/pnas.1322921111.CrossRefPubMedPubMedCentral

177.

Xu, Y., Chao, L., Wang, J., & Sun, Y. (2017). miRNA-148a regulates the expression of the estrogen receptor through DNMT1-mediated DNA methylation in breast cancer cells. Oncology Letters, 14(4), 4736–4740. https://doi.org/10.3892/ol.2017.6803.CrossRefPubMedPubMedCentral

178.

Cho, J. H., Dimri, M., & Dimri, G. P. (2015). MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. The Journal of Biological Chemistry, 290(16), 10555–10567. https://doi.org/10.1074/jbc.M114.624361.CrossRefPubMedPubMedCentral

179.

Song, J., Jin, E. H., Kim, D., Kim, K. Y., Chun, C. H., & Jin, E. J. (2015). MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. BBA Clinical, 3, 79–89. https://doi.org/10.1016/j.bbacli.2014.11.009.CrossRefPubMed

180.

Jiang, S. (2019). MicroRNA Let-7adf in Tet regulation. Aging, 11(14), 4772–4773. https://doi.org/10.18632/aging.102101.CrossRefPubMedPubMedCentral

181.

Fu, X., Jin, L., Wang, X., Luo, A., Hu, J., Zheng, X., et al. (2013). MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 110(44), 17892–17897. https://doi.org/10.1073/pnas.1317397110.CrossRefPubMedPubMedCentral

182.

Cheng, J., Guo, S., Chen, S., Mastriano, S. J., Liu, C., D’Alessio, A. C., et al. (2013). An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Reports, 5(2), 471–481. https://doi.org/10.1016/j.celrep.2013.08.050.CrossRefPubMed

183.

Yang, H., Li, Q., Zhao, W., Yuan, D., Zhao, H., & Zhou, Y. (2014). miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Letters, 588(1), 192–197. https://doi.org/10.1016/j.febslet.2013.11.036.CrossRefPubMed

184.

Nilsson, E. M., Laursen, K. B., Whitchurch, J., McWilliam, A., Odum, N., Persson, J. L., et al. (2015). MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Oncotarget, 6(34), 35710–35725. https://doi.org/10.18632/oncotarget.5958.CrossRefPubMedPubMedCentral

185.

Bao, J., Zou, J. H., Li, C. Y., & Zheng, G. Q. (2016). miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B. European Review for Medical and Pharmacological Sciences, 20(21), 4487–4493.PubMed

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Epigenetic dynamics in cancer stem cell dormancy

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment

FOXO transcription factor family in cancer and metastasis

Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy